Nephrocare Health Services Limited announced significant board decisions during its meeting held on January 05, 2026, focusing on key leadership and governance appointments that require shareholder approval.

Director Re-appointment

The board approved the re-appointment of Mr. Om Prakash Manchanda (DIN: 02099404) as Independent Director for a second term, following recommendations from the Nomination and Remuneration Committee. The appointment details are structured as follows:

Mr. Manchanda has confirmed compliance with regulatory requirements, stating he is not debarred from holding directorship by SEBI or any other authority, as per stock exchange circulars dated June 20, 2018. He brings extensive experience spanning nearly 35 years in medical science and management, including leadership roles at prominent healthcare organizations.

Secretarial Auditor Appointment

The board appointed M/s Makarand M. Joshi & Co., Company Secretaries in Practice, as the company's Secretarial Auditor, based on Audit Committee recommendations. The appointment encompasses:

Ms. Kumudini Paranjahe Bhalerao serves as Senior Partner at the firm and is a Fellow Member of the Institute of Company Secretaries of India (ICSI). She brings extensive experience working with listed, unlisted, and start-up companies across various sectors, providing advisory and audit services.

Meeting Details and Compliance

The board meeting commenced at 06:00 p.m. IST and concluded at approximately 06:20 p.m. IST on January 05, 2026. The announcements were made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Both appointments reflect the company's commitment to strengthening its governance framework through experienced professionals. The re-appointment of Mr. Manchanda ensures continuity in independent oversight, while the new secretarial auditor appointment establishes a long-term partnership for compliance and audit services. Shareholders will vote on both proposals to formalize these appointments.

Polar Capital Funds PLC has increased its shareholding in Nephrocare Health Services Limited through a recent acquisition disclosed under Regulation 29 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition was completed on December 19, 2025, through open market transactions.

Acquisition Details

Polar Capital Funds PLC, through three healthcare funds, acquired an additional 0.214% stake in Nephrocare Health Services, increasing its total holding to 5.057%. The acquisition involved 214,331 shares purchased across three specialized healthcare funds managed by Polar Capital Funds PLC.

Pre and Post-Acquisition Holdings

Before this acquisition, Polar Capital Funds held a combined stake of 4.843% in Nephrocare Health Services totaling 4,859,925 shares. The Healthcare Opportunities Fund dominated the pre-acquisition holdings with 1,846,758 shares representing 4.830% of the company.

Company Share Capital Structure

Nephrocare Health Services maintains a total equity share capital of 100,340,717 shares, which remains unchanged both before and after this acquisition. The company's shares are listed on both BSE and NSE exchanges. Polar Capital Funds PLC does not belong to the promoter or promoter group of Nephrocare Health Services.

Transaction Characteristics

The acquisition was executed entirely through open market purchases on December 19, 2025, with no involvement of preferential allotment, rights issue, or other special arrangements. The disclosure indicates that Polar Capital holds no encumbered shares, warrants, convertible securities, or voting rights other than those arising from equity shareholding in the target company. The regulatory filing was signed by Stephen Amoah from London, UK, on December 22, 2025, confirming compliance with Indian securities regulations.